An Affinity Threshold for Maximum Efficacy in Anti-PD-1 Cancer Immunotherapy
Monoclonal antibodies (mAbs) targeted to the programmed cell death protein 1 (PD-1) remain the most prevalent cancer immunotherapy both as a monotherapy and in combination with additional therapies. Despite the extensive success of anti-PD-1 mAbs in the clinic, the experimental relationship between...
Main Author: | |
---|---|
Other Authors: | |
Format: | Thesis |
Published: |
Massachusetts Institute of Technology
2022
|
Online Access: | https://hdl.handle.net/1721.1/144968 https://orcid.org/ 0000-0002-2246-6333 |